ORIC anticipates the following upcoming data milestones: ORIC -114: 1H 2025: 2L EGFR exon 20 and 2L+ HER2 exon 20; 2H 2025: 2L+ EGFR atypical; 1H 2026: 1L EGFR exon 20; Mid-2026: 1L EGFR exon 20 ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...